United Kingdom (GB)

Frailty and in-hospital outcomes in percutaneous coronary interventions (2019) Kwok CS, Achenbach S, Curzen N, Fischman DL, Savage M, Bagur R, Kontopantelis E, et al. Conference contribution Reduction in blood pressure following renal denervation for patients with differing baseline cardiovascular risk (2019) Mahfoud F, Mancia G, Schmieder R, Narkiewicz K, Ruilope L, Schlaich M, Williams B, et al. Conference contribution Perivascular fat attenuation index stratifies the cardiac risk associated with high-risk plaque features on coronary computed tomography angiography (2019) Oikonomou EK, Mancio J, Kotanidis CK, Thomas KE, Alashi A, Centeno EH, Antonopoulos AS, et al. Conference contribution Safeguarding 5G-and-Beyond Networks with Physical Layer Security (2019) Wu Y, Duong TQ, Swindlehurst AL Journal article, Editorial Facilitated Data Relay and Effects on Treatment of Severe Aortic Stenosis in Europe (2019) Steeds RP, Lutz M, Thambyrajah J, Serra A, Schulz E, Maly J, Aiello M, et al. Journal article Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations (2019) Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. Conference contribution KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) (2019) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, et al. Conference contribution Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen (2019) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution Relation between objective tumour shrinkage and progression-free survival (PFS) in the NETTER-1 population (2019) Pavel ME, Broberg P, Caplin M, Ruszniewski P, Strosberg J, Santoro P, Ravasi L, Krenning E Conference contribution Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer (2019) Fasching P, Huang M, Cortes J, Zhao J, O'Shaughnessy J, Hu P, Haiderali A, et al. Conference contribution